Výsledky vyhledávání - "and Akinori Kubo"

Akademický článek

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)

Abstract De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differe

Externí odkaz: https://doaj.org/article/43aee090e3ba45919e598547b44a7092

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication

Autor: Masato Nakai, Yoshiya Yamamoto, Masaru Baba, Goki Suda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Ken Furuya, Naoya Sakamoto

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)

Abstract Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive facto

Externí odkaz: https://doaj.org/article/7d4cef0345414ea29ae87e92e6a05592

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)

Abstract We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were r

Externí odkaz: https://doaj.org/article/703302c7229a498a89aac76fc46f3e58

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

Publikováno v: Liver Cancer (2022)

Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevac

Externí odkaz: https://doaj.org/article/479658ebbf534b088e03eafa8651074d

Zobrazit plný text záznamu

Akademický článek

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Autor: Naoki Kawagishi, Goki Suda, Megumi Kimura, Osamu Maehara, Ren Yamada, Yoshimasa Tokuchi, Akinori Kubo, Takashi Kitagataya, Taku Shigesawa, Kazuharu Suzuki, Masatsugu Ohara, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Naoya Sakamoto

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)

Abstract We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational per

Externí odkaz: https://doaj.org/article/9f05ad0e9c3c4bdcaf4b034a07202f1e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

Autor: Masato Nakai, Goki Suda, Koji Ogawa, Sonoe Yoshida, Shunichi Hosoda, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Ren Yamada, Taku Shigesawa, Masatsugu Ohara, Takuya Sho, Kenichi Morikawa, Naoya Sakamoto

Publikováno v: PLoS ONE, Vol 17, Iss 7, p e0270786 (2022)

Covert hepatic encephalopathy (CHE) impairs patient quality of life and occurs in approximately 30% of liver cirrhosis (LC) cases. Japanese clinical practice guidelines recommend rifaximin to treat overt HE (OHE). However, the usefulness of rifaximin

Externí odkaz: https://doaj.org/article/1d943d2a6d3244fbafd93ce5eb259fa1

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.

Autor: Taku Shigesawa, Goki Suda, Megumi Kimura, Osamu Maehara, Yoshimasa Tokuchi, Akinori Kubo, Ren Yamada, Ken Furuya, Masaru Baba, Takashi Kitagataya, Kazuharu Suzuki, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto

Publikováno v: PLoS ONE, Vol 16, Iss 3, p e0247728 (2021)

A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks aft

Externí odkaz: https://doaj.org/article/16bae927b72644ca84cea6b21b691046

Zobrazit plný text záznamu

Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection

Publikováno v: Journal of Viral Hepatitis. 29:976-985

Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current state of HBV markers after KT from donors with resolved HBV infectio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e340314d3865265076266ea190dc059
https://doi.org/10.1111/jvh.13740

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání